

B1 cont

Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

A2

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

2. (Amended) A compound of the formula:



B' cont

Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, or CF_3; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, $S(=O)_2NR^5R^6$, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

A2 R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

5. (Amended) A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

6. (Amended) A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, or $S(=O)_2$ NR^5R^6; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

9. (Amended) A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a

with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

10. (Amended) A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, or $S(=O)_2NR^5R^6$; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2NR^5R^6$; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

13. (Amended) A method for treating retinal diseases selected from the group consisting of glaucoma, age related macular degeneration (ARMD), optic neuritis, ischemic disorders, diabetic retinopathy, and retinal edema which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

14. (Amended) A method for treating retinal diseases selected from the group consisting of glaucoma, age related macular degeneration (ARMD), optic neuritis, ischemic disorders, diabetic retinopathy, and retinal edema which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, or $S(=O)_2$ NR^5R^6; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

Sub C1

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

A5

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

---

17. (Amended) A composition for lowering IOP comprising a pharmaceutically

A6



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

A6

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

18. (Amended) A composition for lowering IOP comprising a pharmaceutically effective amount of a compound of the formula:

effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, or $S(=O)_2$ NR^5R^6; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-}

$_{3}$alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

A6 n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

21. A composition for improving blood flow to the optic nerve head and the retina comprising a pharmaceutically effective amount of a compound of the formula:

A7



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be

unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

22. (Amended) A composition for improving blood flow to the optic nerve head and the retina comprising a pharmaceutically effective amount of a compound of the formula:



A7

Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, or $S(=O)_2$ NR^5R^6; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

A7

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

25. (Amended) A composition for treating retinal diseases selected from the group consisting of glaucoma, age related macular degeneration (ARMD), optic neuritis, ischemic disorders, diabetic retinopathy, and retinal edema comprising a pharmaceutically effective amount of a compound of the formula:

A8



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally

with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

A9

26. (Amended) A composition for treating retinal diseases selected from the group consisting of glaucoma, age related macular degeneration (ARMD), optic neuritis, ischemic disorders, diabetic retinopathy, and retinal edema comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, or $S(=O)_2$ NR^5R^6; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-}$

$_{3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

A8

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

39. (Amended) A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, circadian rhythm disorders, and centrally and peripherally mediated hypertension, which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:

A9

Sub C1



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, $S(=O)_2NR^5R^6$, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

40. (Amended) A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythem disorders, and centrally and peripherally mediated hypertension which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, or $S(=O)_2$ NR^5R^6; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, $S(=O)_2$ NR^5R^6, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be

unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates.

43. (Amended) A composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts or solvates in a pharmaceutically acceptable carrier.

44. (Amended) A composition comprising a pharmaceutically effective amount of a compound of the formula:

B2 cont



A10 Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, or $S(=O)_2$ NR^5R^6; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-